n, ethinyl estradiol is a substrate for the drug transporter P-glycoprotein (P-gp); velpatasvir is a P-gp inhibitor.
Ethinyl Estradiol; Etonogestrel: Use caution when administering velpatasvir with ethinyl estradiol. Taking these drugs together may increase the plasma concentrations velpatasvir and ethinyl estradiol, potentially resulting in adverse events. Velpatasvir is a CYP2B6 and CYP3A4 substrate; ethinyl estradiol is an in vitro inhibitor of CYP2B6 and CYP3A4. In addition, ethinyl estradiol is a substrate for the drug transporter P-glycoprotein (P-gp); velpatasvir is a P-gp inhibitor.
Ethinyl Estradiol; Levonorgestrel: Use caution when administering velpatasvir with ethinyl estradiol. Taking these drugs together may increase the plasma concentrations velpatasvir and ethinyl estradiol, potentially resulting in adverse events. Velpatasvir is a CYP2B6 and CYP3A4 substrate; ethinyl estradiol is an in vitro inhibitor of CYP2B6 and CYP3A4. In addition, ethinyl estradiol is a substrate for the drug transporter P-glycoprotein (P-gp); velpatasvir is a P-gp inhibitor.
Ethinyl Estradiol; Levonorgestrel; Folic Acid; Levomefolate: Use caution when administering velpatasvir with ethinyl estradiol. Taking these drugs together may increase the plasma concentrations velpatasvir and ethinyl estradiol, potentially resulting in adverse events. Velpatasvir is a CYP2B6 and CYP3A4 substrate; ethinyl estradiol is an in vitro inhibitor of CYP2B6 and CYP3A4. In addition, ethinyl estradiol is a substrate for the drug transporter P-glycoprotein (P-gp); velpatasvir is a P-gp inhibitor.
Ethinyl Estradiol; Norelgestromin: Use caution when administering velpatasvir with ethinyl estradiol. Taking these drugs together may increase the plasma concentrations velpatasvir and ethinyl estradiol, potentially resulting in adverse events. Velpatasvir is a CYP2B6 and CYP3A4 substrate; ethinyl estradiol is an in vitro inhibitor of CYP2B6 and CYP3A4. In addition, ethinyl estradiol is a substrate for the drug transporter P-glycoprotein (P-gp); velpatasvir is a P-gp inhibitor.
Ethinyl Estradiol; Norethindrone Acetate: Use caution when administering velpatasvir with ethinyl estradiol. Taking these drugs together may increase the plasma concentrations velpatasvir and ethinyl estradiol, potentially resulting in adverse events. Velpatasvir is a CYP2B6 and CYP3A4 substrate; ethinyl estradiol is an in vitro inhibitor of CYP2B6 and CYP3A4. In addition, ethinyl estradiol is a substrate for the drug transporter P-glycoprotein (P-gp); velpatasvir is a P-gp inhibitor.
Ethinyl Estradiol; Norethindrone Acetate; Ferrous fumarate: Use caution when administering velpatasvir with ethinyl estradiol. Taking these drugs together may increase the plasma concentrations velpatasvir and ethinyl estradiol, potentially resulting in adverse events. Velpatasvir is a CYP2B6 and CYP3A4 substrate; ethinyl estradiol is an in vitro inhibitor of CYP2B6 and CYP3A4. In addition, ethinyl estradiol is a substrate for the drug transporter P-glycoprotein (P-gp); velpatasvir is a P-gp inhibitor.
Ethinyl Estradiol; Norethindrone: Use caution when administering velpatasvir with ethinyl estradiol. Taking these drugs together may increase the plasma concentrations velpatasvir and ethinyl estradiol, potentially resulting in adverse events. Velpatasvir is a CYP2B6 and CYP3A4 substrate; ethinyl estradiol is an in vitro inhibitor of CYP2B6 and CYP3A4. In addition, ethinyl est |
